| 10/09/2018 | RxAff | Center for Drug Evaluation and Research | Finished Pharmaceuticals/Unapproved New Drug/Misbranded | Not Issued * |
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Tuesday, October 23, 2018
| 10/09/2018 | MyRxAffiliate Program | Center for Drug Evaluation and Research | Finished Pharmaceuticals/Unapproved New Drug/Misbranded | Not Issued * |
| 10/09/2018 | TeraPharm | Center for Drug Evaluation and Research | Finished Pharmaceuticals/Unapproved New Drug/Misbranded | Not Issued |
Monday, October 22, 2018
Court rules on pharmacist's claim of $100 million in damages
Pharmacy News-46 minutes ago
A pharmacist who claimed $100 million damages from his local shire has been awarded $30,000 by The Federal Court. The ruling culminates an eight-year
Looks Like the USA is not the only one with this issue:
'Pharmacy is big business'
Australian Journal of Pharmacy (blog)-19 hours ago
This includes donations from the Pharmacy Guild of Australia's Queensland branch to the state's political parties during 2018—most recently, $11,000 was ...
DeWine, Cordray both support revamp of drug middlemen
Massillon Independent-16 hours ago
John Kasich, announced in August that it would tell the state's five Medicaid managed-care plans to update their contracts with pharmacy middlemen that
Promise Pharmacy Issues Voluntary Nationwide Recall of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% Sterile Due to Small Particulate Floating in the Solution OCTOBER 22, 2018
Promise Pharmacy is voluntarily recalling one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3ml vials,to the patient consumer level. The product has been found to have unidentified small particulate floating in the solution.
To date Promise Pharmacy has not received any reports of adverse events related to this recall. Potential adverse health consequences could range from limited eye irritation, inflammation and visual impairment to permanent ocular damage with the use of this eye drop solution.
The product is used as a post-surgical (cataract) ophthalmic treatment and was distributed Nationwide to individual patients.
Lot Number 09042018@2, Exp. 12/03/2018 is the only affected lot.
Promise Pharmacy is notifying its prescribers and patients by telephone and mail and is arranging for return/replacement/refund of all recalled product
Patients who have product that is being recalled should stop using it and return it to Promise Pharmacy. Patients will be sent packaging with a prepaid shipping label to facilitate prompt return of product to the pharmacy.
Prescribers and patients with questions regarding this recall can contact Promise Pharmacy at (727) 772-0500 x233 Monday through Friday between the hours of 9:00 am and 3:30 pm EST, or via email to mark@promisepharmacy.com. Patients should contact their prescribing physician if they have experienced any problems that may be related to using this product.
Adverse reactions or quality problems associated with the use of this product may be reported to FDA’s MedWatch Adverse Event Reporting program either by phone, on line, by regular mail or by fax.
Pharmacist launches petition opposing responsible pharmacist ...
The Pharmaceutical Journal-12 hours ago
A pharmacist has started a petition calling on the government to reject responsible pharmacist proposals, which has already received more than 1,800 ..
Subscribe to:
Posts (Atom)